Concepedia

Thomas Yau

TY

Statistics

Publications

9

Citations

1.1K

H-Index

9

Active since

2018

Affiliations

Asan Medical Center(Current)

University of Ulsan

Chinese University of Hong Kong

National Taiwan University Hospital

Samsung Medical Center

Thomas Yau is an author at Asan Medical Center specializing in oncology, hepatocellular carcinoma pharmacotherapy, and hepatocellular carcinoma treatment.

ORCID

Publications per year

2018–2022

9

Publications

9

Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial

Robin Kate Kelley, Lorenza Rimassa, Ann‐Lii Cheng et al. · The Lancet Oncology · 2022 · 522 citations · Full text

, , +17

Nivolumab in advanced hepatocellular carcinoma: Sorafenib-experienced Asian cohort analysis

Thomas Yau, Chiun Hsu, Tae‐You Kim et al. · Journal of Hepatology · 2019 · 269 citations · Full text

, , +17

Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with <i>RAS</i>-Mutated Hepatocellular Carcinoma

Ho Yeong Lim, Philippe Merle, Karl Weiss et al. · Clinical Cancer Research · 2018 · 82 citations · Full text

, , +17

A first-in-human phase 1/2 study of FGF401 and combination of FGF401 with spartalizumab in patients with hepatocellular carcinoma or biomarker-selected solid tumors

Stephen L. Chan, Martin Schüler, Yoon‐Koo Kang et al. · Journal of Experimental & Clinical Cancer Research · 2022 · 77 citations · Full text

, , +16

Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma

Robin Kate Kelley, Patrick Mollon, Jean‐Frédéric Blanc et al. · Advances in Therapy · 2020 · 59 citations · Full text

, , +9

1–5 of 9